Evidence map›Paper›PMID 40518462›Full record

ArticleAnnals of nuclear medicine2025

From planar to SPECT-CT brain perfusion study in brain death determination: our experience from 2010 to 2023.

Mathieu Charest, Marc-André Bélair

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mathieu CharestNuclear Medicine Department, Hôpital du Sacré-Coeur de Montréal, CIUSSS du Nord-de-l'Île-de-Montréal, 5400, boul. Gouin Ouest, Montréal, QC, H4J 1C5, Canada. mathieu.charest@gmail.com.ORCID http://orcid.org/0000-0002-5230-5792
Marc-André BélairNuclear Medicine Department, Hôpital du Sacré-Coeur de Montréal, CIUSSS du Nord-de-l'Île-de-Montréal, 5400, boul. Gouin Ouest, Montréal, QC, H4J 1C5, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadionuclide brain perfusion studies using a lipophilic radiopharmaceutical are recognized as reliable ancillary tests for brain death determination in various clinical guidelines. We aim to share our experience with the SPECT-CT protocol. MATERIALS AND

methodsAll studies performed between 2010 and 2023 were included. Planar, SPECT, and SPECT-CT images were analyzed and categorized as showing normal intracranial perfusion, residual cerebellar activity, definitive absence of intracranial perfusion, or residual intracranial activity. These findings were compared with the final diagnosis for each study, which was based on available clinical information, radiologic, and nuclear medicine images.

resultsA total of 117 brain perfusion studies for brain death determination were performed. Of these, 106 (91%) were reported as definitive for the absence of intracranial perfusion and were concordant with the clinical diagnosis of brain death. In the remaining 11 cases, 5 (4%) showed normal brain perfusion, and 6 (5%) demonstrated residual intracranial activity. Among the 5 studies with normal perfusion, all (100%) were correctly identified on planar-only images. Of the 106 patients with a definitive diagnosis of absent brain perfusion, 56.6% (60/106) showed a definitive planar result, 36.8% (39/106) had a probable result, 3.8% (4/106) showed possible intracranial activity, and in 2.8% (3/106), planar images were not performed. A total of 105 studies with tomographic images were analyzed. Of the 4 studies showing residual cerebellar activity, all (100%) were correctly identified on SPECT images. Of the 98 studies with definitive absence of intracranial perfusion, 91.8% (90/98) showed no cerebral activity on tomographic images. The remaining 8.2% (8/98) showed mild cerebral activity. Notably, 5 of these patients underwent SPECT-CT imaging, and were correctly reclassified as having intracranial bleeding, which led to a final diagnosis of absent brain perfusion. For the 53 SPECT-CT studies analyzed, all patients were correctly categorized as either having absent brain perfusion or residual cerebellar perfusion, with no cases of normal perfusion or residual cerebral perfusion observed. Challenging cases are also discussed, including 3 patients who underwent repeat brain perfusion studies after an initial normal or inconclusive report.

conclusionsIn this article, we share our experience with brain perfusion studies in brain death determination and the evolution of our protocol over the past decade. SPECT-CT has become our standard protocol, allowing us to confidently categorize patients as having either normal brain perfusion, absent brain perfusion, or residual partial brain perfusion. This approach reflects the clinical need for an unbiased and accurate test of intracranial perfusion.

Indexed as

BrainBrain DeathPerfusion ImagingSingle Photon Emission Computed Tomography Computed TomographyAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultBrain death determinationHMPAOLipophilic tracerProtocolSPECTSPECT-CT

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.